---
title: "Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations"
description: "Formulary evidence on Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations. 1 evidence topic quoted from 0 sources."
canonical: "https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations"
published: "2026-11-18T22:38:31-05:00"
modified: "2026-11-18T22:38:31-05:00"
---

# Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations

<a id="terms-and-abbreviations"></a>

## Terms and Abbreviations

<a id="topic-terms-and-abbreviations-1"></a>

| Abbreviation | Term |
| --- | --- |
| 12W | 12 weeks |
| AAAAI | American Academy of Allergy, Asthma & Immunology |
| AAbs | Autoantibodies |
| AAD | American Academy of Dermatology |
| AAS | Angioedema Activity Score |
| AAS28 | Angioedema Activity Score 4-week sum score |
| AAS7 | Weekly Angioedema Activity Score |
| ACAAI | American College of Allergy, Asthma & Immunology |
| ACE | Angiotensin-converting enzyme |
| AD | Atopic dermatitis |
| ADA | Antidrug antibodies |
| AE, AEs | Adverse event; angioedema (in recurrent AE) |
| AECT | Angioedema Control Test |
| AHFS | American Hospital Formulary Service |
| aiCSU | Autoimmune chronic spontaneous urticaria |
| AIDs | Autoimmune diseases |
| ANC | Absolute neutrophil count |
| ANCOVA | Analysis of covariance |
| ANOVA | Analysis of variance |
| APAC | All Payer All Claims |
| A-PP | AAAAI Practice Parameter Update 2014 |
| ASST | Autologous serum skin test |
| aTPO, anti-TPO | Anti-thyroid peroxidase (antibody) |
| AUC | Area under the concentration-time curve; area under the receiver operating characteristic curve |
| BASO | Basophil test |
| BAT | Basophil activation test |
| BHRA | Basophil histamine release assay |
| bIgE | Total IgE before treatment (baseline) |
| BIM | Budget impact model |
| BL | Baseline |
| BLA | Biologics License Application |
| BMI | Body mass index |
| BNF | British National Formulary |
| BTK | Bruton's tyrosine kinase |
| C1 | Complement component 1 |
| C1q | Complement component 1q |
| CA | California |
| CAPS | Cryopyrin-associated periodic syndromes |
| CBC | Complete blood count |
| CC | Complete control |
| CD | Celiac disease |
| CD117 | Cluster of differentiation 117 (KIT) |
| CD34 | Cluster of differentiation 34 |
| CD63 | Cluster of differentiation 63 |
| CDM | Clinformatics Data Mart |
| CDMOs | Contract development & manufacturing organizations |
| CDX-0158 | Celldex development code for the predecessor anti-KIT antibody of barzolvolimab, with an unmodified IgG1/κ backbone |
| CDX-0159 | Celldex development code for barzolvolimab |
| CENTRAL | Cochrane Central Register of Controlled Trials |
| CFB | Change from baseline |
| cGMP | Current Good Manufacturing Practice |
| CH50 | 50% hemolytic complement (total complement activity) |
| CHO | Chinese hamster ovary |
| CI, CIs | Confidence interval |
| CI95% | 95% confidence interval |
| CIndU, CIndUs, CINDU | Chronic inducible urticaria |
| CIU | Chronic idiopathic urticaria |
| c-Kit, c-KIT | Cellular KIT (KIT receptor tyrosine kinase) |
| c-Kitl | c-Kit ligand (stem cell factor) |
| CLDX | Nasdaq ticker symbol of Celldex Therapeutics |
| Cmax | Maximum serum concentration |
| ColdU | Cold urticaria |
| COVID-19 | Coronavirus disease 2019 |
| COX-2 | Cyclooxygenase-2 |
| CR | Complete response |
| CrI | Credible interval |
| CRP | C-reactive protein |
| CRSwNP | Chronic rhinosinusitis with nasal polyps |
| CsA | Cyclosporine A |
| CSU | Chronic spontaneous urticaria |
| CSUaiTIIb | Chronic spontaneous urticaria of autoimmune type IIb |
| CTIS | Clinical Trials Information System |
| CT-P39 | Celltrion development code for an omalizumab biosimilar |
| CU | Chronic urticaria |
| CU-Q2oL | Chronic Urticaria Quality of Life Questionnaire |
| CYP3A4 | Cytochrome P450 3A4 |
| DALYs | Disability-adjusted life years |
| DD | Diagnostic delay |
| Diff | Difference |
| diff | Differential (white blood cell count) |
| DLQI | Dermatology Life Quality Index |
| DP | Drug Product |
| DS | Drug Substance |
| DSQ | Dysphagia Symptom Questionnaire |
| EAACI | European Academy of Allergy and Clinical Immunology |
| EADV | European Academy of Dermatology & Venereology |
| EAPC | Estimated annual percentage change |
| EC50 | Half-maximal effective concentration |
| ED | Emergency department |
| EHR, EHRs | Electronic Health Record |
| EMBASE | Excerpta Medica Database |
| EoE | Eosinophilic esophagitis |
| EQ-5D, EQ-5D-3L | EuroQol 5-Dimension questionnaire; EuroQol 5-Dimension 3-Level questionnaire |
| EREFS | Eosinophilic Esophagitis Endoscopic Reference Score (endoscopic scoring of EoE-related inflammation & fibrosis) |
| ESR | Erythrocyte sedimentation rate |
| EU | European Union |
| FACAAI | Fellow of the American College of Allergy, Asthma and Immunology |
| Fc | Fragment crystallizable (region of an antibody) |
| FcRn | Neonatal Fc receptor |
| FcγR | Fc gamma receptor |
| FcεRI, FcϵRI, FcεR1 | High-affinity IgE receptor (Fc epsilon receptor I) |
| FDA | Food and Drug Administration |
| FDLQI | Family Dermatology Life Quality Index |
| FU, FU1, FU2 | Follow-up; follow-up visit 1; follow-up visit 2 |
| G2, G3, G4 | Grade 2, grade 3, grade 4 |
| GAD-7 | Generalized Anxiety Disorder 7-item scale |
| GBD | Global Burden of Disease |
| GDP | Gross domestic product |
| GLP | Good Laboratory Practice |
| GRADE | Grading of Recommendations Assessment, Development and Evaluation |
| H1 | Histamine type 1 (receptor) |
| H1-AH, H1-AHs, H1AH | H1-antihistamine (H1AH: Type 1 antihistamine) |
| H2 | Histamine type 2 (receptor) |
| HAE | Hereditary angioedema |
| HCRU | Healthcare resource utilization |
| HIV | Human immunodeficiency virus |
| HMC-1.2 | Human mast cell line 1, subclone 2 |
| HR | Hazard ratio |
| HRQoL | Health-related quality of life |
| HRU | Health care resource utilization |
| HSS | Hives Severity Score |
| HSS7 | Weekly Hives Severity Score |
| huKIT-D4D5 | Membrane proximal dimerization domains (Ig 4 and 5) of human KIT |
| HV | Healthy volunteers |
| I2 | I-squared statistic of heterogeneity |
| IC50 | Half-maximal inhibitory concentration |
| ICD-9, ICD-10 | International Classification of Diseases, version 9 and version 10 |
| ICER, ICERs | Incremental cost-effectiveness ratio |
| Ig | Immunoglobulin (immunoglobulin-like domain) |
| IgE | Immunoglobulin E |
| IgG | Immunoglobulin G |
| IgG1 | Immunoglobulin G1 |
| IgG1κ, IgG1/κ | Immunoglobulin G1 kappa |
| IHC | Immunohistochemistry |
| IL | Interleukin |
| IL-4Ra | Interleukin-4 receptor alpha |
| ILC2 | Group 2 innate lymphoid cell |
| INN | International nonproprietary name |
| IQR | Interquartile range |
| ISS | Itch Severity Score |
| ISS7 | Weekly Itch Severity Score |
| IV | Intravenous |
| JTF | Joint Task Force (on Practice Parameters) |
| JTFPP | Joint Task Force on Practice Parameters |
| KIT | Mast/stem cell growth factor receptor KIT (receptor tyrosine kinase) |
| KITD816V | KIT carrying the D816V substitution (aspartic acid to valine at codon 816) |
| LD | Loading dose |
| LLoQ | Lower limit of assay quantitation |
| LS | Least squares |
| LTE | Long-term extension |
| LTRA | Leukotriene receptor antagonist |
| mAb | Monoclonal antibody |
| MAD | Multiple ascending doses |
| MC, MCs | Mast cell |
| MCD | Mean cost difference |
| MCID | Minimal clinically important difference |
| MCS | Mental Component Summary |
| MCTC | Mast cell containing tryptase and chymase |
| MD | Mean difference; Doctor of Medicine |
| MEDLINE | Medical Literature Analysis and Retrieval System Online |
| MH | Mental health |
| MID | Minimal important difference |
| mITT | Modified intent-to-treat |
| MMRM | Mixed model for repeated measures |
| MRGPRX2 | Mas-related G-protein coupled receptor member X2 |
| NASDAQ | National Association of Securities Dealers Automated Quotations |
| NE | Not estimable |
| NHP | Nottingham Health Profile |
| NHWS | National Health and Wellness Survey |
| NICE | National Institute for Health and Care Excellence |
| N.J., NJ | New Jersey |
| nsAH | Non-sedating H1-antihistamine |
| NSAIDs | Nonsteroidal anti-inflammatory drugs |
| OR | Odds ratio |
| OX40 | OX40 receptor (tumor necrosis factor receptor superfamily member 4) |
| OX40L | OX40 ligand |
| PAF | Platelet activation factor |
| PatGA | Patients Global Assessment |
| PCS | Physical Component Summary |
| PD | Pharmacodynamics |
| PGD2 | Prostaglandin D2 |
| PHQ-9 | Patient Health Questionnaire 9-item |
| PhysGA, PhyGA | Physician Global Assessment |
| PK | Pharmacokinetics |
| PN | Prurigo nodularis |
| PPP, PPP$ | Purchasing power parity; purchasing power parity dollars |
| PPPY | Per patient per year |
| PPQ | Process Performance Qualification |
| PROMs | Patient-reported outcome measures |
| PsO, PSO | Psoriasis |
| PTA | Patent term adjustment |
| PTE | Patent term extension |
| Q2W | Every 2 weeks |
| Q4 | Fourth quarter of a calendar year |
| Q4W | Every 4 weeks |
| Q4 WK | Every 4 weeks |
| Q8W | Every 8 weeks |
| Q8 WK | Every 8 weeks |
| QALY, QALYs | Quality-adjusted life-year |
| QID | Four times daily |
| QoL | Quality of life |
| RA | Rheumatoid arthritis; recurrent angioedema (in the AECT validation quote) |
| RCT, RCTs | Randomized controlled trial |
| RD | Risk difference |
| RecA | Recurrent angioedema |
| ref-OMA | Reference omalizumab |
| ROC | Receiver operating characteristic |
| SAE, SAEs | Serious adverse event |
| SC | Subcutaneous |
| SCF | Stem cell factor |
| sCSU | Standalone chronic spontaneous urticaria |
| SD | Standard deviation; symptomatic dermographism |
| SDC | Smallest detectable change |
| SE, SEs | Standard error |
| SF-6D | Short Form 6-Dimension |
| sgAH, sgAHs | Second-generation antihistamine |
| sgH1-AH | Second-generation H1-antihistamine |
| SG-H1AHs | Second-generation H1-antihistamines |
| Siglec-8 | Sialic acid-binding immunoglobulin-like lectin 8 |
| SOC, SoC | Standard of care |
| T1R3 | Taste receptor type 1 member 3 |
| TEAE, TEAEs | Treatment-emergent adverse event |
| TKIs | Tyrosine kinase inhibitors |
| TNF-α | Tumor necrosis factor-alpha |
| TP1, TPs | Treatment period 1; treatment periods |
| TPO | Thyroid peroxidase |
| TSH | Thyroid-stimulating hormone |
| UAS | Urticaria Activity Score |
| UAS7, UAS7s | Weekly Urticaria Activity Score (sum of daily scores over 7 days) |
| UAS7TD | Weekly Urticaria Activity Score from twice-daily assessments of itch and hives |
| UCARE | Urticaria Centres of Reference and Excellence |
| UCT | Urticaria Control Test |
| UCT7 | Urticaria Control Test, 7-day recall |
| UK | United Kingdom |
| US, U.S. | United States |
| USA | United States of America |
| UTI, UTIs | Urinary tract infection |
| V1, V18 | Version 1, version 18 (ClinicalTrials.gov record history) |
| VAT | Value-added tax |
| vs, vs. | Versus |
| W48, W52, W76 | Week 48, Week 52, Week 76 |
| w4IgE | Total IgE 4 weeks after the start of treatment |
| WAC | Wholesale acquisition cost |
| WBC | White blood count |
| WK | Week |
| WT | Wild-type |
| WTP | Willingness to pay |
| YTE | M252Y/S254T/T256E Fc substitutions |

## Related pages
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria.md)
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic information and modeling report](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: References](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references.md)
